[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100231429":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":20,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Rigshospitalet, Denmark","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"tumor biopsy","EXPERIMENTAL","Tumor biopsy for targeted treatment according to molecular profile",[13],"Procedure: Tumor biopsy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Tumor biopsy","Biopsy of lesion for molecular characterization",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Ulrik Lassen, MD, PH.D.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":20},"Ida V Tuxen, MD","CONTACT","+4535453545",{"name":23,"role":28,"phone":29,"phoneExt":20,"email":20},[32],{"facility":33,"status":34,"city":35,"state":20,"zip":20,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Rigshospitalet","RECRUITING","Copenhagen","Denmark","DK",{"type":39,"coordinates":40},"Point",[41,42],12.56553,55.67594,{"lat":42,"lon":41},[45],{"name":46,"role":24,"phone":20,"phoneExt":20,"email":20},"Ulrik Lassen, MD, PH.D",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Ulrik Lassen","MD, PH.D","100231429","copenhagen-prospective-personalized-oncology-coppo-100231429",false,"NCT02290522","Copenhagen Prospective Personalized Oncology (CoPPO)","A Prospective Study Using Genomic Screening to Select Patients for Targeted Molecular Treatment","CoPPO","Inclusion Criteria:\n\n* Solid tumor\n* No standard treatment option\n* PS 0-1\n* Lesion assessable for biopsy\n* Measurable disease\n* Informed consent\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 3 months\n* Bone marrow suppression\n* Abnormal renal or hepatic function\n* Serious concurrent medical conditions","ALL","18 Years",{"count":62,"type":63},500,"ESTIMATED","INTERVENTIONAL",[66],"NA","Patients with advanced solid tumors referred to the Phase 1 Unit are offered mapping of GA for identification of pts who could benefit from a personalized treatment.",[69],"Unspecified Adult Solid Tumor, Protocol Specific","2026-08-11",{"date":72,"type":73},"2026-08-12","ACTUAL",{"date":75,"type":73},"2013-05-01",{"date":77,"type":63},"2029-12-31",{"name":49,"class":6},1]